What We have Learned about Pain from Rodent Models of Arthritis?

被引:0
|
作者
Inglis, Julia J. [1 ,2 ]
Schutze, Mark U. [3 ]
McNamee, Kay E. [4 ]
机构
[1] Murdoch Univ, Sch Vet & Biomed Sci, Perth, WA, Australia
[2] Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA, Australia
[3] Sir Charles Gairdner Hosp, Dept Pain Management, Perth, WA, Australia
[4] Imperial Coll London, London W6 8LH, England
关键词
Pain mechanisms; animal models; rodent; osteoarthritis; rheumatoid arthritis; analgesics;
D O I
10.2174/157339710791792748
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rheumatoid arthritis (RA) and Osteoarthritis (OA) are both common diseases of the joints. RA is distinguished by inflammation and synovitis leading to joint destruction, whereas OA is typified by degenerative and mostly noninflammatory disease. Although differing in their pathology, both forms can elicit chronic disabling pain in patients. Relief from this pain is an unmet need for many patients, and this has lead to a drive to understand the pain mechanisms occurring in each disease in order to develop new analgesics. This necessitates the use of pre-clinical models. Here we discuss the methods and limitations of animal pain assessment, rodent models of RA and OA, and how these models have been used to investigate the genesis of pain. Specifically, we focus on processes studied in both RA and OA models, and how the mediators involved in the development of pain may differ between these two arthritic states and during acute and chronic pain. From this we have learnt that the key mediators of RA pain include inflammatory cells, inflammatory cytokines, astrocytes, substance P, and CGRP. Endogenous analgesic mediators in RA include beta-endorphin, mu-opioid receptor, and various anti-inflammatory cytokines. Less is known of the mediators of OA pain, but important factors include CGRP, TRPV1, NGF, VIP and the mu-opioid receptor. Interestingly, several factors have been found not to play a role in OA pain, including glial cells, neutrophils and TNF. It must be noted that the vast majority of candidate drugs from animal research never reach the human clinic, in part due to false positives from animal models. This may be due to flaws in the models themselves, the methods used to assess pain, the physical properties of the candidate drug, or an inherent difference between animal and human pain pathways. By developing more clinically relevant models, novel diseasespecific analgesics are being developed with the hope of improving the quality of life for sufferers of arthritis pain.
引用
收藏
页码:194 / 207
页数:14
相关论文
共 50 条
  • [21] Fungal x host interactions in chromoblastomycosis What we have learned from animal models and what is yet to be solved
    Salgado, Claudio Guedes
    VIRULENCE, 2010, 1 (01) : 3 - 5
  • [22] The Pathophysiology of Sleep Apnoea: What We have Learned from Animal Models of Chronic Intermittent Hypoxia
    O'Halloran, Ken D.
    Bradford, Aidan
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2007, 3 (01) : 19 - 27
  • [23] What have we learned from animal models of idiosyncratic, drug-induced liver injury?
    Roth, Robert A.
    Ganey, Patricia E.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (06) : 475 - 491
  • [24] A "Furry-Tale' of Zika Virus Infection: What Have We Learned from Animal Models?
    Nazerai, Loulieta
    Christensen, Jan Pravsgaard
    Thomsen, Allan Randrup
    VIRUSES-BASEL, 2019, 11 (01):
  • [25] Cardiovascular Dysfunction Following Burn Injury: What We Have Learned from Rat and Mouse Models
    Guillory, Ashley N.
    Clayton, Robert P.
    Herndon, David N.
    Finnerty, Celeste C.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (01)
  • [26] ANCA-small vessel vasculitides: what have we (not yet) learned from animal models?
    Van Der Veen, Betty S.
    Heeringa, Peter
    APMIS, 2009, 117 : 21 - 26
  • [27] Alveolus formation: what have we learned from genetic studies?
    Yan, C
    Du, H
    JOURNAL OF APPLIED PHYSIOLOGY, 2004, 97 (04) : 1543 - 1548
  • [28] Experiencing painful osteoarthritis: what have we learned from listening?
    Hawker, Gillian A.
    CURRENT OPINION IN RHEUMATOLOGY, 2009, 21 (05) : 507 - 512
  • [29] Antibodies to citrullinated proteins/peptides in rheumatoid arthritis: what have we learned so far?
    Kuna, Andrea Tesija
    Zirovic, Marijana
    BIOCHEMIA MEDICA, 2008, 18 (03) : 275 - 290
  • [30] Animal models in mycology: What have we learned over the past 30 years
    Kirkpatrick W.R.
    Wiederhold N.P.
    Najvar L.K.
    Patterson T.F.
    Current Fungal Infection Reports, 2013, 7 (1) : 68 - 78